Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. (Q44142664)

From Wikidata

Jump to navigation Jump to search

scientific article published on 12 December 2012

Language	Label	Description	Also known as
English	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.	scientific article published on 12 December 2012

Statements

scholarly article

1 reference

Europe PubMed Central

30 November 2017

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. (English)

1 reference

Europe PubMed Central

30 November 2017

0 references

bipolar disorder

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

13

1 reference

Europe PubMed Central

30 November 2017

17

1 reference

Europe PubMed Central

30 November 2017

21

1 reference

Europe PubMed Central

30 November 2017

object named as

David J Bond

14

0 references

18

object named as

Boris Birmaher

1 reference

Europe PubMed Central

30 November 2017

Benício N Frey

object named as

Benicio N Frey

15

0 references

Roger S McIntyre

9

object named as

Roger S McIntyre

1 reference

Europe PubMed Central

30 November 2017

Benjamin I Goldstein

16

object named as

Benjamin I Goldstein

1 reference

Europe PubMed Central

30 November 2017

Claire O'Donovan

7

object named as

Claire O'Donovan

1 reference

Europe PubMed Central

30 November 2017

20

object named as

Willem A Nolen

1 reference

Europe PubMed Central

30 November 2017

Lakshmi N Yatham

1

object named as

Lakshmi N Yatham

1 reference

Europe PubMed Central

30 November 2017

Glenda MacQueen

8

object named as

Glenda Macqueen

1 reference

Europe PubMed Central

30 November 2017

Sidney H. Kennedy

2

object named as

Sidney H Kennedy

1 reference

Europe PubMed Central

30 November 2017

4

object named as

Ayal Schaffer

1 reference

Europe PubMed Central

30 November 2017

Verinder Sharma

10

object named as

Verinder Sharma

1 reference

Europe PubMed Central

30 November 2017

author name string

Sagar V Parikh

3

1 reference

Europe PubMed Central

30 November 2017

Serge Beaulieu

5

1 reference

Europe PubMed Central

30 November 2017

Martin Alda

6

1 reference

Europe PubMed Central

30 November 2017

Arun Ravindran

11

1 reference

Europe PubMed Central

30 November 2017

L Trevor Young

12

1 reference

Europe PubMed Central

30 November 2017

Kyooseob Ha

19

1 reference

Europe PubMed Central

30 November 2017

publication date

12 December 2012

1 reference

Europe PubMed Central

30 November 2017

Bipolar Disorders

1 reference

Europe PubMed Central

30 November 2017

15

1 reference

Europe PubMed Central

30 November 2017

1

1 reference

Europe PubMed Central

30 November 2017

1-44

1 reference

Europe PubMed Central

30 November 2017

Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Differences in prevalence and treatment of bipolar disorder among immigrants: results from an epidemiologic survey

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Suicide attempts in bipolar I and bipolar II disorder: a review and meta-analysis of the evidence

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Suicide and suicide attempts in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Absolute risk of suicide after first hospital contact in mental disorder.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Self-esteem in remitted bipolar disorder patients: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Mixed states vs. pure mania in the French sample of the EMBLEM study: results at baseline and 24 months--European mania in bipolar longitudinal evaluation of medication

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Course and outcome after the first manic episode in patients with bipolar disorder: prospective 12-month data from the Systematic Treatment Optimization Program For Early Mania project

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Longitudinal course of bipolar I disorder: duration of mood episodes

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Diagnostic guidelines for bipolar disorder: a summary of the International Society for Bipolar Disorders Diagnostic Guidelines Task Force Report.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Enhanced relapse prevention for bipolar disorder by community mental health teams: cluster feasibility randomised trial.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Enhancing multiyear guideline concordance for bipolar disorder through collaborative care.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Early warning signs checklists for relapse in bipolar depression and mania: utility, reliability and validity.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A randomized controlled trial of psychoeducation or cognitive-behavioral therapy in bipolar disorder: a Canadian Network for Mood and Anxiety treatments (CANMAT) study [CME].

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Family-focused treatment for caregivers of patients with bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Clinician-assisted Internet-based treatment is effective for depression: randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Randomized effectiveness trial of an Internet, pure self-help, cognitive behavioral intervention for depressive symptoms in young adults

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Developing an online psychoeducation package for bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Efficacy of sodium valproate and haloperidol in the management of acute mania: a randomized open-label comparative study

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A 12-week, open, randomized trial comparing sodium valproate to lithium in patients with bipolar I disorder suffering from a manic episode

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A randomized, placebo-controlled, multicenter study of divalproex sodium extended-release in the acute treatment of mania

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Aripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Asenapine versus olanzapine in acute mania: a double-blind extension study

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Effects of stimulus intensity on the efficacy and safety of twice-weekly, bilateral electroconvulsive therapy (ECT) combined with antipsychotics in acute mania: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: a pilot study

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A single-blind, comparative study of zotepine versus haloperidol in combination with a mood stabilizer for patients with moderate-to-severe mania

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Folic acid efficacy as an alternative drug added to sodium valproate in the treatment of acute phase of mania in bipolar disorder: a double-blind randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Early symptom change and prediction of subsequent remission with olanzapine augmentation in divalproex-resistant bipolar mixed episodes.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Treatment options for bipolar depression: a systematic review of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8-week open label trial

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Comparative response to electroconvulsive therapy in medication-resistant bipolar I patients with depression and mixed state.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Comparison of electroconvulsive therapy (ECT) with or without anti-epileptic drugs in bipolar disorder.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Electroconvulsive therapy is equally effective in unipolar and bipolar depression.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Effect of aripiprazole on self-reported anhedonia in bipolar depressed patients.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Patterns of Psychotropic Drug Prescription for U.S. Patients With Diagnoses of Bipolar Disorders

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Effectiveness of adjunctive antidepressant treatment for bipolar depression

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Do we need to flick the switch? The need for a broader conceptualization of iatrogenic course aggravation in clinical trials of bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Predictors of nonadherence among individuals with bipolar disorder receiving treatment in a community mental health clinic

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Assessment of medication adherence in a cohort of patients with bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Predictors of medication nonadherence and hospitalization in Medicaid patients with bipolar I disorder given long-acting or oral antipsychotics

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Poor adherence to treatment associated with a high recurrence in a bipolar disorder outpatient sample.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Indirect costs associated with nonadherence to treatment for bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

The relationship between antipsychotic medication adherence and patient outcomes among individuals diagnosed with bipolar disorder: a retrospective study

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Twelve-month prospective, multinational, observational study of factors associated with recovery from mania in bipolar disorder in patients treated with atypical antipsychotics.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

2-Year course of bipolar disorder type I patients in outpatient care: factors associated with remission and functional recovery.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Influence of atypical features on the quality of prophylactic effectiveness of long-term lithium treatment in bipolar disorders.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Cognitive-behavioral therapy for depression in bipolar disorder: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Cognitive behavioural therapy for major psychiatric disorder: does it really work? A meta-analytical review of well-controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A randomized controlled trial of cognitive behavioral group therapy for bipolar disorder.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

The effectiveness of cognitive behavioral group therapy in treating bipolar disorder: a randomized controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical trial.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A brief dyadic group based psychoeducation program improves relapse rates in recently remitted bipolar disorder: a pilot randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6).

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Effectiveness of olanzapine monotherapy and olanzapine combination treatment in the long term following acute mania--results of a two year observational study in bipolar disorder (EMBLEM).

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127).

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126).

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study).

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Comparison of carbamazepine and lithium in treatment of bipolar disorder: a systematic review of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and Co-occurring substance abuse or dependence

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Risperidone in the treatment of mixed state bipolar patients: results from a 24-week, multicenter, open-label study in Korea

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Longitudinal follow-up of bipolar disorder in women with premenstrual exacerbation: findings from STEP-BD.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Association of seasonality and premenstrual symptoms in bipolar I and bipolar II disorders.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

The impact of premenstrual dysphoric disorder among 92 bipolar patients.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Pregnancy outcome after in utero exposure to valproate : evidence of dose relationship in teratogenic effect

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Valproic acid monotherapy in pregnancy and major congenital malformations

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Selective serotonin reuptake inhibitors and risk for major congenital anomalies.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Atypical antipsychotic use in pregnancy: a retrospective review

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Screening for bipolar disorder during pregnancy and the postpartum period

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Screening for postpartum bipolar disorder: validation of the Mood Disorder Questionnaire.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A longitudinal study of hypomania and depression symptoms in pregnancy and the postpartum period.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Bipolar II postpartum depression: Detection, diagnosis, and treatment

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

DSM-V: modifying the postpartum-onset specifier to include hypomania

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Postpartum bipolar episodes are not distinct from spontaneous episodes: implications for DSM-V.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Risks and predictors of readmission for a mental disorder during the postpartum period.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Psychotic illness in first-time mothers with no previous psychiatric hospitalizations: a population-based study

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Increased depressive symptoms in menopausal age women with bipolar disorder: age and gender comparison

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Global burden of disease in young people aged 10-24 years: a systematic analysis

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

National trends in the outpatient diagnosis and treatment of bipolar disorder in youth

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Meta-analysis of epidemiologic studies of pediatric bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Recent progress in understanding pediatric bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Pediatric bipolar disorder: validity, phenomenology, and recommendations for diagnosis

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Concerns regarding the inclusion of temper dysregulation disorder with dysphoria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Four-year longitudinal course of children and adolescents with bipolar spectrum disorders: the Course and Outcome of Bipolar Youth (COBY) study

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Child bipolar I disorder: prospective continuity with adult bipolar I disorder; characteristics of second and third episodes; predictors of 8-year outcome

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Twelve-month outcome of adolescents with bipolar disorder following first hospitalization for a manic or mixed episode

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Bipolar disorder among adolescents and young adults: results from an epidemiological sample.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Comparison of manic and depressive symptoms between children and adolescents with bipolar spectrum disorders

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Pharmacological and non-drug treatment of child bipolar I disorder during prospective eight-year follow-up

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Predictors of prospectively examined suicide attempts among youth with bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Clinical and psychosocial correlates of non-suicidal self-injury within a sample of children and adolescents with bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Comorbid anxiety in children and adolescents with bipolar spectrum disorders: prevalence and clinical correlates

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A controlled family study of children with DSM-IV bipolar-I disorder and psychiatric co-morbidity

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Psychosocial functioning, familiality, and psychiatric comorbidity in bipolar youth with and without psychotic features

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A cohort study of the prevalence and impact of comorbid medical conditions in pediatric bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Preliminary findings regarding overweight and obesity in pediatric bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Preliminary findings regarding proinflammatory markers and brain-derived neurotrophic factor among adolescents with bipolar spectrum disorders

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Family-focused treatment for adolescents with bipolar disorder: results of a 2-year randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Early psychosocial intervention for youth at risk for bipolar I or II disorder: a one-year treatment development trial

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Dialectical behavior therapy for adolescents with bipolar disorder: a 1-year open trial

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Interpersonal and social rhythm therapy for adolescents with bipolar disorder: treatment development and results from an open trial

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Practice parameter on the use of psychotropic medication in children and adolescents

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

FDA panel OKs 3 antipsychotic drugs for pediatric use, cautions against overuse

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Maintenance treatment of adolescent bipolar disorder: open study of the effectiveness and tolerability of quetiapine

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Rapid quetiapine loading in youths with bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Psychosocial functioning and health-related quality of life in children and adolescents treated with open-label ziprasidone for bipolar mania, schizophrenia, or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Comparative clinical responses to risperidone and divalproex in patients with pediatric bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Impact of obsessive-compulsive disorder on the antimanic response to olanzapine therapy in youth with bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Response to second generation antipsychotics in youth with comorbid bipolar disorder and autism spectrum disorder.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A prospective open-label trial of lamotrigine monotherapy in children and adolescents with bipolar disorder.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Enhanced working and verbal memory after lamotrigine treatment in pediatric bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Effectiveness of lamotrigine in maintaining symptom control in pediatric bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Long-term safety of divalproex sodium extended-release in children and adolescents with bipolar I disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A prospective open-label trial of extended-release carbamazepine monotherapy in children with bipolar disorder.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Depression symptom ratings in geriatric patients with bipolar mania.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Cognitive dysfunction and medical morbidity in elderly outpatients with bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Anticonvulsant use, bipolar disorder, and risk of fracture among older adults in the Veterans Health Administration

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

The longitudinal course of cognition in older adults with bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Selective deficit of autobiographical incident memory in subjects with bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Longitudinal analysis of cognitive performances and structural brain changes in late-life bipolar disorder.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Cognitive impairment in early and late bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

The relationship of bipolar disorder lifetime duration and vascular burden to cognition in older adults.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Risk factors for cognitive impairment in elderly bipolar patients

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Lithium treatment and risk of dementia.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Quetiapine for the treatment of bipolar mania in older adults

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Multisite, open-label, prospective trial of lamotrigine for geriatric bipolar depression: a preliminary report.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Prevalence and burden of general medical conditions among adults with bipolar I disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Manic/hypomanic symptom burden and cardiovascular mortality in bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

The incidence of cardiovascular morbidity among patients with bipolar disorder: a population-based longitudinal study in Ontario, Canada

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Bipolar disorder and metabolic syndrome: an international perspective

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

The rate of metabolic syndrome in euthymic Canadian individuals with bipolar I/II disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Can body mass index help predict outcome in patients with bipolar disorder?

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

The association of weight gain with mood symptoms and functional outcomes following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

The burden of obesity among adults with bipolar disorder in the United States

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Impact of comorbid migraine on the clinical course of bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

On the prevalence of bipolar disorder in epilepsy

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Comorbid anxiety and substance use disorders associated with a lower use of mood stabilisers in patients with rapid cycling bipolar disorder: a descriptive analysis of the cross-sectional data of 566 patients

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Effect of comorbid alcohol and drug use disorders on premature death among unipolar and bipolar disorder decedents in the United States, 1999 to 2006.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Increased risk for suicidal behavior in comorbid bipolar disorder and alcohol use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC).

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Cannabis involvement in individuals with bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Tobacco smoking behaviors in bipolar disorder: a comparison of the general population, schizophrenia, and major depression

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Cigarette smoking is associated with suicidality in bipolar disorder.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Clinical features, response to treatment and functional outcome of bipolar disorder patients with and without co-occurring substance use disorder: 1-year follow-up

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Substance abuse and switch from depression to mania in bipolar disorder.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Sustained unemployment in psychiatric outpatients with bipolar disorder: frequency and association with demographic variables and comorbid disorders

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Clinical significance of lifetime panic disorder in the course of bipolar disorder type I.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Anxiety and outcome in bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Prevalence and correlates of eating disorders in 875 patients with bipolar disorder.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Misdiagnosis of bipolar disorder as borderline personality disorder: clinical and economic consequences

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Borderline personality disorder and the misdiagnosis of bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A history of childhood attention-deficit hyperactivity disorder (ADHD) impacts clinical outcome in adult bipolar patients regardless of current ADHD.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Bipolar disorders and quality of life: the impact of attention deficit/hyperactivity disorder and substance abuse in euthymic patients

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Is the collaborative chronic care model effective for patients with bipolar disorder and co-occurring conditions?

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Development of an integrated psychosocial treatment to address the medical burden associated with bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Open adjunctive ziprasidone associated with weight loss in obese and overweight bipolar disorder patients

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Bariatric surgery: 1-year weight loss outcomes in patients with bipolar and other psychiatric disorders

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A "community-friendly" version of integrated group therapy for patients with bipolar disorder and substance dependence: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Psychotherapies for comorbid anxiety in bipolar spectrum disorders

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Medical and substance use comorbidity in bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Quetiapine monotherapy as treatment for anxiety symptoms in patients with bipolar depression: a pooled analysis of results from 2 double-blind, randomized, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Placebo-controlled study of quetiapine monotherapy in ambulatory bipolar spectrum disorder with moderate-to-severe hypomania or mild mania

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Randomized, double-blind, placebo-controlled study of divalproex extended release loading monotherapy in ambulatory bipolar spectrum disorder patients with moderate-to-severe hypomania or mild mania

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Role of risperidone in bipolar II: an open 6-month study.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Psychotherapy as monotherapy for the treatment of bipolar II depression: a proof of concept study

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive bipolar I or II depression: a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Divalproex extended-release in acute bipolar II depression

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trial

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Venlafaxine monotherapy in bipolar type II depressed patients unresponsive to prior lithium monotherapy

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

The use of triiodothyronine as an augmentation agent in treatment-resistant bipolar II and bipolar disorder NOS.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Psychoeducation for bipolar II disorder: an exploratory, 5-year outcome subanalysis.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Adjunctive lamotrigine therapy for patients with bipolar II depression partially responsive to mood stabilizers.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Role of lamotrigine in the management of treatment-resistant bipolar II depression: a chart review

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Quetiapine and classical mood stabilizers in the long-term treatment of Bipolar Disorder: a 4-year follow-up naturalistic study.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Long-term effectiveness of quetiapine in bipolar disorder in a clinical setting

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Transition to mania during treatment of bipolar depression

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Illness risk following rapid versus gradual discontinuation of antidepressants

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Meta-analytic review of neurocognition in bipolar II disorder.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Psychotic versus non-psychotic bipolar II disorder.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Progression along the bipolar spectrum: a longitudinal study of predictors of conversion from bipolar spectrum conditions to bipolar I and II disorders

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Low-dose quetiapine for patients with dysregulation of hyperthymic and cyclothymic temperaments

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Prevalence of diabetes in patients with bipolar disorder in Taiwan: a population-based national health insurance study

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

The role of valproate in metabolic disturbances in bipolar disorder patients

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Association between mood stabilizers and hypothyroidism in patients with bipolar disorders: a nested, matched case-control study

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Lithium toxicity profile: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Treatment of suicide attempters with bipolar disorder: a randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Meta-analyses of cognitive functioning in euthymic bipolar patients and their first-degree relatives.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A meta-analytic investigation of neurocognitive deficits in bipolar illness: profile and effects of clinical state

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Neurocognitive functions in euthymic bipolar patients

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A comparison of neuropsychological dysfunction in first-episode psychosis patients with unipolar depression, bipolar disorder, and schizophrenia

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Comparison of neuropsychological effects of adjunctive risperidone or quetiapine in euthymic patients with bipolar I disorder.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: a nested matched case-control study.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Rash in adult patients receiving lamotrigine to treat bipolar I disorder in Korea: a multicenter, prospective, naturalistic, open-label trial.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Feasibility of a slower lamotrigine titration schedule for bipolar depression: a naturalistic study

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

The association between depressive and anxiety symptoms and bone mineral density in the general population: the HUNT Study.

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Work impairment in bipolar disorder patients – results from a two-year observational study (EMBLEM)

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Efficacy and Safety of Lamotrigine as Add-On Treatment to Lithium in Bipolar Depression

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Bipolar disorder in the elderly; different effects of age and of age of onset

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Antidepressant-Induced Mania with Concomitant Mood Stabilizer in Patients with Comorbid Substance Abuse and Bipolar Disorder

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Group-based psychosocial intervention for bipolar disorder: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FBDI.12025

21 January 2018

Identifiers

10.1111/BDI.12025

1 reference

Europe PubMed Central

30 November 2017

1 reference

Europe PubMed Central

30 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44142664&oldid=2107073833"